Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupEndocrine and Neuroendocrine OncologyThoracic TumorsTumor, regardless of entityDiseaseLung Carcinoma, Non-Small CellThyroid CancerTumor Biomarker DefinedSubgroupanaplasticBRAF V600E mutationmedullaryRET fusion positiveICD10C34.-C73MeSHNeoplasmsThyroid Carcinoma, AnaplasticThyroid NeoplasmsSequenceChemotherapyChemo-substanceCabozantinibCarboplatinCisplatinDabrafenibDoxorubicinLenvatinibPaclitaxelPembrolizumabPralsetinibSelpercatinibSorafenibTrametinibVandetanibChemo-substanceCabozantinibCarboplatinCisplatinDabrafenibDoxorubicinLenvatinibPaclitaxelPembrolizumabPralsetinibSelpercatinibSorafenibTrametinibVandetanibChemo-substanceCabozantinibCarboplatinCisplatinDabrafenibDoxorubicinLenvatinibPaclitaxelPembrolizumabPralsetinibSelpercatinibSorafenibTrametinibVandetanibChemo-substanceCabozantinibCarboplatinCisplatinDabrafenibDoxorubicinLenvatinibPaclitaxelPembrolizumabPralsetinibSelpercatinibSorafenibTrametinibVandetanibNo. Substances12 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesium sulfatePegfilgrastimPotassium chlorideNo. Substances1247Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleTherapy phaseTherapy intentionpalliativeRisksAlopeciaAnemia Hb below 8g/dlAnemia Hb below 10g/dlAnorexiaArthalgiaAstheniaBleedingCardiotoxicityConstipationDiarrheaDysphagiaDyspneaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaFistulasHand-Foot SyndromeHeadacheHemorrhageHepatotoxicityHyperglycemiaHyperphosphatemiaHypertensionHypocalcemiaIncrease AminotransferasesLeukopeniaMucositisNeuropathyNeutropeniaOral MucositisPneumoniaPneumonitisProteinuriaPyrexiaQTc Time ExtensionRashRenal FailureThrombocytopenia below 50 000/µlThromboembolic EventVomiting only studiesPublicationAuthorBrose MDierks CDrilon AElisei ROnoda NSchlumberger MShimaoka KSosa JASubbiah VWells SDiseaseAnaplastisches Schilddrüsenkarzinom, lokal fortgeschritten oder metastasiert, ECOG 0-2Anaplastisches Schilddrüsenkarzinom, RET-fusionspositivDifferenziertes Schilddrüsenkarzinom, papillär / follikulär, nach Iod-131, Rezidivtherapie, ECOG 0-1fortgeschrittenes oder metastasiertes Schilddrüsenkarzinom, refraktär auf radioaktive Iodtherapie, ECOG 0-3lokal fortgeschrittenes oder metastasiertes, differenziertes Schilddrüsenkarzinom, refraktär auf radioaktive Iodtherapie, ECOG 0-2lokal fortgeschrittenes oder metastasiertes anaplastisches Schilddrüsenkarzinom, BRAF V600E mutiert, ECOG 0-2nichtresezierbares, lokal fortgeschrittenes oder metastasiertes medulläres Schilddrüsenkarzinom, ECOG 0-2nicht resezierbares, lokal fortgeschrittenes oder metstasiertes medulläres Schilddrüsenkarzinom, ECOG 0-2RET-bedingte Tumoren, Zweitlinie oder höher, ECOG 0-2Schilddrüsenkarzinom, lokal fortgeschritten oder metastasiertOriginAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA, COSMIC-311Department of Hematology and Oncology, University Halle-Wittenberg, Halle, GermanyDepartment of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy and University Paris-Sud, FranceDepartment of Otorhinolaryngology: Head and Neck Surgery, and Abramson Cancer Center of the University of Pennsylvania, Philadelphia, DECISION trialDepartment of Surgery, Duke University School of Medicine , Durham, North CarolinaMemorial Sloan Kettering Cancer Center and Weill Cornell Medical College, LIBRETTO-001National Cancer Institute, National Institutes of Health, Bethesda, MDProspective Clinical Study Committee of Anaplastic Thyroid Carcinoma Research Consortium of Japan, Tokyo, JapanRoswell Park Memorial Institute, Buffalo, New YorkThe University of Texas MD Anderson Cancer Center, Houston, ROAR basket studyThe University of Texas MD Anderson Cancer Center, Houston, USA, ARROW trialUniversity of Pisa, Milan, Italy, EXAMProtocols in Revision 13 protocols foundProtocols under revision.Cabozantinib 140, Thyroid Cancer (PID825 V1.2)Cabozantinib 60, Thyroid Cancer (PID2834 V1.0)Cisplatin 40 / Doxorubicin 60, Thyroid Cancer (PID2140 V1.0)Dabrafenib 150 / Trametinib 2, Thyroid Cancer (PID1419 V1.0)Doxorubicin 60, Thyroid Cancer (PID2137 V1.0)Lenvatinib 24 / Pembrolizumab 200, Thyroid Cancer (PID2161 V1.0)Lenvatinib 24, Thyroid Cancer (PID824 V1.0)Paclitaxel 200 / Carboplatin 6, Thyroid Cancer (PID2136 V1.0)Paclitaxel 80, Thyroid Cancer (PID2135 V1.0)Pralsetinib 400, Thyroid Cancer (PID2141 V1.0)Selpercatinib 160, Tumor Biomarker Defined (PID1732 V1.0)Sorafenib 400, Thyroid Cancer (PID751 V1.1)Vandetanib 300, Thyroid Cancer (PID1380 V1.0)
